Sheeba K Thomas

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
    Jatin J Shah
    Departments of Lymphoma Myeloma
    Ther Clin Risk Manag 5:151-9. 2009
  2. doi request reprint Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0429, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 73:35-42. 2014
  3. doi request reprint Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial
    Sheeba K Thomas
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 39:253-62. 2012
  4. doi request reprint Novel agents for relapsed and/or refractory multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030 4009, USA
    Cancer J 15:485-93. 2009
  5. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
  6. pmc Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
    Elisabeth G Vichaya
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 71:1531-40. 2013
  7. pmc Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    Deborah J Kuhn
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 120:3260-70. 2012
  8. ncbi request reprint Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:118-22. 2012
  9. pmc Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
    Sally A Hunsucker
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Br J Haematol 152:579-92. 2011
  10. ncbi request reprint Lenalidomide in multiple myeloma
    Sheeba K Thomas
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 20:717-35. 2007

Collaborators

Detail Information

Publications14

  1. pmc Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
    Jatin J Shah
    Departments of Lymphoma Myeloma
    Ther Clin Risk Manag 5:151-9. 2009
    ..Efforts are now underway to build on this combination further by adding other active anti-myeloma agents. In this review, we will discuss the role of PLD+B as an important addition to our therapeutic armamentarium for patients with MM...
  2. doi request reprint Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 0429, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 73:35-42. 2014
    ..A phase 1 study evaluated the QTc prolongation potential of siltuximab, a chimeric, anti-interleukin-6 mAb, in patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or low-volume MM...
  3. doi request reprint Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial
    Sheeba K Thomas
    Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 39:253-62. 2012
    ..A first-in-human study is planned to evaluate its use in patients with asymptomatic phase lymphoplasmacytic lymphoma...
  4. doi request reprint Novel agents for relapsed and/or refractory multiple myeloma
    Sheeba K Thomas
    Division of Cancer Medicine, Department of Lymphoma Myeloma, University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Unit 429, Houston, TX 77030 4009, USA
    Cancer J 15:485-93. 2009
    ..In this review, we will discuss the use of these novel agents and their combinations in patients with relapsed and/or refractory multiple myeloma...
  5. pmc Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Am J Hematol 87:272-6. 2012
    ..Further studies should be conducted in carefully designed clinical trials in this patient population...
  6. pmc Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy
    Elisabeth G Vichaya
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Chemother Pharmacol 71:1531-40. 2013
    ..g., pain and numbness) in patients with MM undergoing treatment with chemotherapy...
  7. pmc Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
    Deborah J Kuhn
    Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA
    Blood 120:3260-70. 2012
    ....
  8. ncbi request reprint Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 53:118-22. 2012
    ..These results indicate that high-dose melphalan plus auto HCT is safe and feasible for patients with multiple myeloma aged ≥70 years and age alone should not be an exclusion criterion for auto HCT...
  9. pmc Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma
    Sally A Hunsucker
    Department of Lymphoma and Myeloma, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Br J Haematol 152:579-92. 2011
    ..These studies provide a rationale for translation of siltuximab into the clinic in combination with melphalan-based therapies...
  10. ncbi request reprint Lenalidomide in multiple myeloma
    Sheeba K Thomas
    The University of Texas M D Anderson Cancer Center, Department of Lymphoma and Myeloma, 1515 Holcombe Blvd, Box 429, Houston, TX 77030, USA
    Best Pract Res Clin Haematol 20:717-35. 2007
    ..We describe the role of lenalidomide in patients with symptomatic multiple myeloma that is newly diagnosed, relapsed and/or refractory to other therapies, or concurrent with primary amyloidosis...
  11. pmc Validation of the M. D. Anderson Symptom Inventory multiple myeloma module
    Desiree Jones
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, 77030, Houston, TX 77030, USA
    J Hematol Oncol 6:13. 2013
    ..We sought to validate a module of the M. D. Anderson Symptom Inventory (MDASI) developed specifically for patients with MM (MDASI-MM)...
  12. ncbi request reprint Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy
    Valerie Reed
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:4468-74. 2011
    ..The objective of this study was to review the outcome of patients with solitary plasmacytoma (SP) after definitive radiation therapy...
  13. pmc Effect of long-term storage in TRIzol on microarray-based gene expression profiling
    Wencai Ma
    The Myeloma Tissue and Leukemia Satellite Sample Banks, Department of Lymphoma and Myeloma, University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Epidemiol Biomarkers Prev 19:2445-52. 2010
    ....
  14. pmc Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty
    Tito R Mendoza
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pain 13:564-70. 2012
    ....